{
    "ticker": "AVTX",
    "name": "Avalo Therapeutics, Inc.",
    "description": "Avalo Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare genetic diseases and other serious conditions. Founded in 2018 and headquartered in Rockville, Maryland, Avalo uses its proprietary technology platforms to discover and develop drug candidates that target unmet medical needs, particularly in metabolic diseases and genetic disorders. The company is dedicated to advancing its pipeline of product candidates through clinical development and aims to bring effective treatments to patients who face limited or no treatment options. Avalo's lead product candidates focus on both rare diseases and broader therapeutic areas, leveraging advanced scientific research and collaboration with healthcare professionals to create impactful solutions. The company is committed to patient-centric approaches and works closely with the patient community to understand their needs and challenges. As it progresses through clinical trials, Avalo aims to contribute to the field of precision medicine and improve the quality of life for patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Rockville, Maryland, USA",
    "founded": "2018",
    "website": "https://www.avalotx.com",
    "ceo": "David A. Pritchard",
    "social_media": {
        "twitter": "https://twitter.com/Avalotx",
        "linkedin": "https://www.linkedin.com/company/avalotx"
    },
    "investor_relations": "https://investors.avalotx.com",
    "key_executives": [
        {
            "name": "David A. Pritchard",
            "position": "CEO"
        },
        {
            "name": "Alfredo A. Ochoa",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "AVTX-002",
                "AVTX-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Avalo Therapeutics, Inc. | Innovative Therapies for Rare Diseases",
        "meta_description": "Explore Avalo Therapeutics, Inc., a biotechnology company committed to developing innovative treatments for rare genetic diseases and unmet medical needs.",
        "keywords": [
            "Avalo Therapeutics",
            "Biotechnology",
            "Rare Diseases",
            "Genetic Disorders",
            "AVTX-002",
            "AVTX-101"
        ]
    },
    "faq": [
        {
            "question": "What does Avalo Therapeutics focus on?",
            "answer": "Avalo Therapeutics focuses on developing innovative therapies for rare genetic diseases and other serious conditions."
        },
        {
            "question": "Who is the CEO of Avalo Therapeutics?",
            "answer": "David A. Pritchard is the CEO of Avalo Therapeutics, Inc."
        },
        {
            "question": "Where is Avalo Therapeutics headquartered?",
            "answer": "Avalo Therapeutics is headquartered in Rockville, Maryland, USA."
        },
        {
            "question": "What are Avalo Therapeutics' main products?",
            "answer": "Avalo Therapeutics' main product candidates include AVTX-002 and AVTX-101."
        },
        {
            "question": "When was Avalo Therapeutics founded?",
            "answer": "Avalo Therapeutics was founded in 2018."
        }
    ],
    "competitors": [
        "SNDX",
        "PTCT",
        "RARE",
        "SRNE"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "GILD",
        "REGN"
    ]
}